Skip to main navigation
Skip to search
Skip to main content
Sort by
Pharmacology, Toxicology and Pharmaceutical Science
Vancomycin
100%
Pharmacokinetics
81%
Pharmacodynamics
56%
Therapeutic Drug Monitoring
53%
Infection
50%
Teicoplanin
39%
Linezolid
35%
Retrospective Study
32%
Minimum Inhibitory Concentration
31%
Adverse Event
31%
Nephrotoxicity
28%
Methemoglobin
26%
Voriconazole
26%
Mouse
26%
Acute Kidney Failure
25%
Pharmacokinetic
24%
Hepatotoxicity
23%
Antiinfective Agent
23%
Cmin
20%
Methicillin Resistant Staphylococcus Aureus Infection
20%
Thrombocytopenia
19%
Daptomycin
19%
Carbon Monoxide
19%
Chemotherapy
18%
Methicillin-Resistant Staphylococcus Aureus
17%
Adverse Drug Reaction
16%
Metronidazole
16%
Antibiotics
15%
Hydrogen Sulfide
15%
Nacubactam
15%
Penicillinase
13%
Sultamicillin
12%
Toxic Injury
12%
Liposome
12%
Sulbactam
11%
Meningitis
11%
Muscle Atrophy
11%
Cefmetazole
11%
Ceftriaxone
11%
Antifungal Agent
11%
Ampicillin
11%
Amphotericin B
10%
Randomized Controlled Trial
10%
Cyanide Poisoning
10%
Cohort Study
9%
Clarithromycin
9%
Trough Level
9%
Creatinine
9%
Streptococcus pneumonia
8%
Chronic Kidney Failure
8%
Keyphrases
Vancomycin
54%
Therapeutic Drug Monitoring
31%
Area under the Concentration-time Curve
25%
Trough Concentration
23%
Multicenter Retrospective Study
23%
Systematic Meta-analysis
20%
Meta-analysis
20%
Voriconazole
18%
Pharmacokinetics
17%
Odds Ratio
17%
Confidence Interval
16%
Daptomycin
15%
Treatment Efficacy
14%
Nephrotoxicity
14%
Pharmacokinetics-pharmacodynamics (PK-PD)
13%
Acute Kidney Injury
13%
Thrombocytopenia
12%
Teicoplanin
12%
Dose Optimization
12%
Linezolid
11%
Chemotherapy
11%
Ampicillin-sulbactam
11%
Consensus Review
11%
Hollow-fiber Infection Model
11%
Lactams
11%
Cmin
10%
Nacubactam
10%
Adverse Effects
9%
Risk Factors
9%
Renal Function
9%
Hepatotoxicity
9%
Methicillin-resistant Staphylococcus Aureus Infection
9%
Minimum Inhibitory Concentration
8%
Adult Patients
8%
Methicillin-resistant Staphylococcus Aureus
8%
Point Sampling
8%
Pharmacodynamics
8%
Pharmacodynamic Study
8%
Two-point
8%
Clinical Efficacy
7%
Fidaxomicin
7%
Ampicillin
7%
Cystatin C (Cys C)
7%
Tedizolid
7%
Japanese Society
7%
Clinical Practice Guidelines
7%
Elderly Patients
7%
Creatine Phosphokinase
7%
Critically Ill Patients
7%
Sciatic Denervation
7%